Celltrion Launches A Third Tocilizumab Biosimilar To Actemra In US

Intravenous Avtozma Will Be Followed By Subcutaneous Formulation

 
• By Dave Wallace
  
Celltrion is the third firm to compete on biosimilar tocilizumab in the US (Shutterstock)

More from Biosimilars

More from Products